Annie Elong Ngono | Instructor, Center for Infectious Disease and Vaccine Research
La Jolla Institute for Allergy and Immunology

Annie Elong Ngono, Instructor, Center for Infectious Disease and Vaccine Research, La Jolla Institute for Allergy and Immunology

Dr. Annie Elong Ngono is Research Instructor in the Center for Infectious Disease and Vaccine Research at the La Jolla Institute for Immunology (LJI). She received her Ph.D. in Immunology working on the role of autoreactive T and B cells in periphery using blood samples from patients with multiple sclerosis, an autoimmune disease. Her research focus has since broadened, to infectious diseases and mouse models in the group of Dr. Sujan Shresta. She has led key projects aimed at understanding the adaptive immune response to infection with flaviviruses, particularly dengue and Zika viruses. In particular, she developed novel mouse models of sequential infections with dengue and Zika viruses to demonstrate that the cross-reactive anti-flaviviral T cell and antibody responses have the capacity to either protect against or exacerbate clinical disease, depending on the context. Recently, Dr. Elong Ngono has extended her work to investigate the role of pre-existing immunity to human common cold coronaviruses and the interplay between antibody and T cell responses in modulating the outcome of infection with SARS-CoV-2 using various mouse models. In addition, Dr. Elong Ngono has established scientific collaborations with researchers in several endemic countries to investigate emerging virus biology, immunogenicity, and pathogenicity using patient-derived samples, while also building research capacity and viral surveillance on site


WVIC/WAC Day 2 - Nov 30 @ 10:00

Panel: Overcoming obstacles in developing therapeutics for neglected and emerging diseases

  • What are the challenges in designing effective clinical trials for these diseases?
  • What role do platform trials play?
  • What are the key regulatory issues?
  • How would a collaborative nature between researchers and regulatory help with development?
  • Why is funding an issue? What can be done to combat this issue?
  • How to react most efficiently to unexpected disease surges (e.g Monkeypox outbreak)
last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall